CCM
IONS icon

Cadence Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Cadence Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-32,215
Closed -$1.63M – 667
2017
Q3 		$1.63M Buy
32,215
+20,426
+173% +$1.07M 0.1% 248
2017
Q2 		$600K Buy
+11,789
New +$549K 0.04% 482

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Cadence Capital Management's IONS Position: Q4 2017 in Review

Cadence Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2017, closing a stake of 32,215 shares — an estimated $1.63M sold.

Cadence Capital Management first reported a position in IONS in Q2 2017 and held it in 2 quarters. The position peaked at $1.63M in Q3 2017. 316 funds tracked by Wall St. Rank hold IONS as of Q4 2017.

  • Cadence Capital Management reported no remaining Ionis Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Cadence Capital Management sold 32,215 Ionis Pharmaceuticals shares in Q4 2017, an estimated $1.63M.
  • Cadence Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Cadence Capital Management's Ionis Pharmaceuticals position peaked at $1.63M in Q3 2017.
  • 316 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2017.

Based on Cadence Capital Management's 13F filing for Q4 2017, filed 5 Feb 2018.